Quantum Genesis AI Corp. (OTC: QGAI) has issued a statement regarding the Caveat Emptor designation placed on its securities by OTC Markets Group, Inc. on February 12, 2026. The company, which focuses on artificial intelligence, computational modeling, and scientific innovation, has been actively seeking to understand the basis for the designation since it was applied.
In its statement, the company noted that OTC Markets indicated the designation relates to a “public interest concern.” Quantum Genesis AI has requested additional clarification and intends to continue cooperating with OTC Markets to address the matter. The company was recently informed that it may formally request a review of the designation beginning March 13, 2026, and plans to engage at the earliest opportunity.
“We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation,” said Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp. “Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process.”
The Caveat Emptor designation is a warning to investors that there may be a public interest concern associated with the company’s securities. It often leads to reduced liquidity and increased scrutiny from brokers and investors. For Quantum Genesis AI, this designation could impact its ability to attract investment and maintain shareholder confidence.
The company remains committed to transparency and intends to provide updates as more information becomes available. For further details, the company directs stakeholders to visit www.qgaicorp.com and its profile on www.otcmarkets.com/stock/QGAI.
This development underscores the challenges faced by small-cap companies in maintaining compliance with OTC Markets standards. The outcome of the review process will be critical for Quantum Genesis AI as it seeks to restore its standing and reassure investors.
